The EU Commission fines two pharmaceutical companies for "pay-for-delay" patent settlement agreement (Cephalon / Teva)

On 26 November 2020, the European Commission (the Commission) brought to an end a long running competition case by finding against Cephalon and Teva on account of a “pay-for-delay” patent settlement agreement involving modafinil, the active substance of a sleeping disorder medicine

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Van Bael & Bellis (Brussels)
  • Van Bael & Bellis (Brussels)
  • Van Bael & Bellis (Brussels)

Quotation

Peter L'Ecluse, Catherine Longeval, Koen T'Syen, The EU Commission fines two pharmaceutical companies for "pay-for-delay" patent settlement agreement (Cephalon / Teva), 26 November 2020, e-Competitions November 2020, Art. N° 98080

Visites 215

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues